litlas
ログインアカウント作成

Kevin B. Kim

2004–2024 年に発表

55
論文数
19,507
被引用数
42
h 指数
53
i10 指数

被引用数

Kevin B. Kim の年別被引用数2001 年: 被引用 1 件2006 年: 被引用 2 件2007 年: 被引用 1 件2008 年: 被引用 1 件2009 年: 被引用 1 件2010 年: 被引用 52 件2011 年: 被引用 235 件2012 年: 被引用 413 件2013 年: 被引用 560 件2014 年: 被引用 640 件2015 年: 被引用 495 件2016 年: 被引用 356 件2017 年: 被引用 330 件2018 年: 被引用 266 件2019 年: 被引用 642 件2020 年: 被引用 575 件2021 年: 被引用 454 件2022 年: 被引用 362 件2023 年: 被引用 259 件2024 年: 被引用 541 件2025 年: 被引用 321 件2026 年: 被引用 10 件2002〜2005 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,312 件、この内訳の 31.2%中国: 引用元論文 552 件、この内訳の 7.5%イタリア: 引用元論文 431 件、この内訳の 5.8%ドイツ: 引用元論文 415 件、この内訳の 5.6%イギリス: 引用元論文 410 件、この内訳の 5.5%オーストラリア: 引用元論文 392 件、この内訳の 5.3%フランス: 引用元論文 336 件、この内訳の 4.6%オランダ: 引用元論文 232 件、この内訳の 3.1%スイス: 引用元論文 220 件、この内訳の 3%スペイン: 引用元論文 214 件、この内訳の 2.9%カナダ: 引用元論文 190 件、この内訳の 2.6%日本: 引用元論文 126 件、この内訳の 1.7%
0%31.2%その他 21.2%

機関

分野

  • Biochemistry, Genetics and Molecular Biology49.7%
  • Medicine39.3%
  • Immunology and Microbiology4.9%
  • Computer Science2.1%
  • Mathematics0.7%
  • Engineering0.7%
  • その他2.6%

トピック

  • Melanoma and MAPK Pathways14.1%
  • Cutaneous Melanoma Detection and Management6.2%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Immunotherapy and Immune Responses4.3%
  • Computational Drug Discovery Methods4.3%
  • CAR-T cell therapy research3.5%
  • その他62.8%

共著者

全論文

検索で開く
  1. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

    著者: Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, C. Lance Cowey, Andrew L. Pecora, Montaser Shaheen, Jennifer Segar, Theresa Medina, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Jane A Healy, Mo Huang, Manju Morrissey, Igor Feldman, Vasudha Sehgal, Céline Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, Robert Meehan, Tal Zaks - The Lancet 2024 被引用: 739

  2. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

    著者: Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, Jean‐François Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, John M. Kirkwood, Marlana Orloff, Joseph J. Sacco, Sebastian Ochsenreither, Anthony M. Joshua, Lauris Gastaud, Brendan D. Curti, Josep M. Piulats, April K.S. Salama, Alexander N. Shoushtari, Lev Demidov, Mohammed Milhem, Bartosz Chmielowski, Kevin B. Kim, Richard D. Carvajal, Omid Hamid, Laura Collins, Koustubh Ranade, Chris Holland, Constance R. Pfeiffer, Paul Nathan - New England Journal of Medicine 2023 被引用: 261

  3. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    著者: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 被引用: 2,798

  4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

    著者: Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul Lin, Richard J. Lee, Joseph F. Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, K. B. Nolop - Nature 2010 被引用: 1,837

  5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

    著者: Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Peter J. O’Dwyer, Richard J. Lee, Joseph F. Grippo, K. B. Nolop, Paul B. Chapman - New England Journal of Medicine 2010 被引用: 3,536

  6. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    著者: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 被引用: 2,148

  7. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.

    著者: Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, Charles Lance Cowey, Theresa Medina, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Elizabeth I. Buchbinder, Robert Meehan, Matteo S. Carlino, on behalf of Moderna Author's Group - Journal of Clinical Oncology 2023 被引用: 68

  8. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 被引用: 933

  9. NRAS mutation status is an independent prognostic factor in metastatic melanoma

    著者: John Jakob, Roland L. Bassett, Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys Alvarado, Michelle Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu, Michael A. Davies - Cancer 2011 被引用: 690

  10. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    著者: F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder, Jonathan A. Fletcher, Mei‐Jun Zhu, Adrián Mariño‐Enríquez, Philip Friedlander, René González, Jeffrey S. Weber, Thomas F. Gajewski, Steven O’Day, Kevin B. Kim, Donald P. Lawrence, Keith T. Flaherty, Jason J. Luke, Frances A. Collichio, Marc S. Ernstoff, Michael C. Heinrich, Carol Beadling, Katherine Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, George D. Demetri, David E. Fisher - Journal of Clinical Oncology 2013 被引用: 595

  11. Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

    著者: Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, George Ansstas, Theresa Medina, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy B. Tran, C. Lance Cowey, Andrew L. Pecora, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Peijie Hou, Lili Zhu, Tal Zaks, Michelle Brown, Praveen Aanur, Robert Meehan, Jeffrey S. Weber - Cancer Research 2023 被引用: 49

  12. Prognostic factors for survival in melanoma patients with brain metastases

    著者: Michael A. Davies, Ping Liu, Susan McIntyre, Kevin B. Kim, Nicholas Papadopoulos, Wen‐Jen Hwu, Patrick Hwu, Agop Y. Bedikian - Cancer 2010 被引用: 548

  13. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma

    著者: Omid Hamid, Karl D. Lewis, Amy Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve Thomas, Janice M. Mehnert, John M. Kaczmar, Nehal J. Lakhani, Kevin B. Kim, Mark R. Middleton, Guilherme Rabinowits, Alexander I. Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Janković, Fang Wang, Nathalie Fiaschi, Laura K. Brennan, Anne Paccaly, Sheila Masinde, Mark Salvati, Matthew G. Fury, Glenn S. Kroog, Israel Lowy, Giuseppe Gullo - Journal of Clinical Oncology 2024 被引用: 39

  14. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.

    著者: Jeffrey S. Weber, Muhammad Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, Charles Lance Cowey, Theresa Medina, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Elizabeth I. Buchbinder, Georgina V. Long, Robert Meehan - Journal of Clinical Oncology 2024 被引用: 35

  15. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    著者: Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis - Journal of Clinical Oncology 2012 被引用: 477

  16. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher - The Lancet Oncology 2012 被引用: 542

  17. Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

    著者: Georgina V. Long, Jeffrey S. Weber, Jeffrey R. Infante, Kevin B. Kim, Adil Daud, René González, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Richard Kefford, Donald P. Lawrence, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Igor Puzanov, Nageatte Ibrahim, Peng Sun, Elizabeth Cunningham, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, Kiran Klaus Patel, Keith T. Flaherty - Journal of Clinical Oncology 2016 被引用: 287

  18. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

    著者: Douglas B. Johnson, Keith T. Flaherty, Jeffrey S. Weber, Jeffrey R. Infante, Kevin B. Kim, Richard Kefford, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, William H. Sharfman, Robert R. McWilliams, Mario Sznol, Donald P. Lawrence, Geoffrey T. Gibney, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Kiran Klaus Patel, Nageatte Ibrahim, Peng Sun, Shonda M Little, Elizabeth Cunningham, Jeffrey A. Sosman, Adil Daud, René González - Journal of Clinical Oncology 2014 被引用: 212

  19. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

    著者: Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, Thomas A. Davis, Mario Sznol, Patrick Hwu - Journal of Clinical Oncology 2014 被引用: 98

  20. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

    著者: Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria - Clinical Cancer Research 2022 被引用: 42

  21. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

    著者: Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard Kefford, Jean‐Jacques Grob, Omid Hamid, Ravi K. Amaravadi, Ester Simeone, Tabea Wilhelm, Kevin B. Kim, Georgina V. Long, Anne-Marie Martin, Jolly Mazumdar, Vicki Goodman, Uwe Trefzer - Journal of Clinical Oncology 2013 被引用: 427

  22. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma

    著者: Kevin B. Kim, Víctor G. Prieto, Richard W. Joseph, A. Hafeez Diwan, Gary E. Gallick, Nicholas E. Papadopoulos, Agop Y. Bedikian, Luis H. Camacho, Patrick Hwu, Chaan S. Ng, Wei Wei, Marcella M. Johnson, Sabine M. Wittemer, Anna Vardeleon, Aaron Reckeweg, A. Dimitrios Colevas - Melanoma Research 2012 被引用: 75

  23. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

    著者: Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, René González, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey S. Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Patrick A. Ott, Ravi K. Amaravadi, Karl D. Lewis, Igor Puzanov, Roger S. Lo, Astrid Koehler, Mark Kockx, Olivia Spleiss, Annette Schell-Steven, Houston Gilbert, Louise Cockey, Gideon Bollag, Richard J. Lee, Andrew K. Joe, Jeffrey A. Sosman, Antoni Ribas - Journal of Clinical Oncology 2013 被引用: 363

  24. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy

    著者: Yong Qin, Kathryn Bollin, Mariana Petaccia de Macêdo, Fernando C. L. Carapeto, Kevin B. Kim, Jason Roszik, Khalida Wani, Alexandre Reuben, Sujan Reddy, Michelle D. Williams, Michael T. Tetzlaff, Wei‐Lien Wang, Dan S. Gombos, Bita Esmaeli, Alexander J. Lazar, Patrick Hwu, Sapna P. Patel - Journal for ImmunoTherapy of Cancer 2020 被引用: 61